Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine

This publication has 28 references indexed in Scilit:

• Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo‐controlled, double‐blind clinical trial
  British Journal of Dermatology, 2018
• A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas
  Clinical Drug Investigation, 2018
• Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants
  ImmunoHorizons, 2018
• Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants
  Vaccine, 2016
• Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial
  The Lancet Infectious Diseases, 2016
• Rational design of small molecules as vaccine adjuvants
  Science Translational Medicine, 2014
• Dendritic Cell-Targeted Vaccines
  Frontiers in Immunology, 2014
• Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
  Immunity, 2011
• Unmet needs in modern vaccinology
  Vaccine, 2010
• Pemphigus-like lesions induced by imiquimod
  Clinical and Experimental Dermatology, 2009